Cara Therapeutics (NASDAQ:CARA) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a report published on Sunday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Cara Therapeutics Stock Performance

Shares of NASDAQ:CARA opened at $0.27 on Friday. The company has a market cap of $14.71 million, a PE ratio of -0.12 and a beta of 0.70. Cara Therapeutics has a 12-month low of $0.24 and a 12-month high of $1.40. The stock has a 50 day moving average of $0.30 and a 200 day moving average of $0.45.

Cara Therapeutics (NASDAQ:CARA) last announced its quarterly earnings data on Wednesday, August 14th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.10). Cara Therapeutics had a negative net margin of 1,010.20% and a negative return on equity of 241.31%. The company had revenue of $0.99 million for the quarter, compared to analysts’ expectations of $1.26 million. Equities research analysts predict that Cara Therapeutics will post -1.24 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cara Therapeutics

A hedge fund recently bought a new stake in Cara Therapeutics stock. Marquette Asset Management LLC acquired a new position in shares of Cara Therapeutics, Inc. (NASDAQ:CARA) during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 94,238 shares of the biopharmaceutical company’s stock, valued at approximately $86,000. Marquette Asset Management LLC owned approximately 0.17% of Cara Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 44.66% of the company’s stock.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.